These compounds demonstrated antiproliferative activity in cancer cells by inhibiting KDM2A, KDM7A, and KDM7B.576 Similarly, Gerken et al.577 developed a series of novel KDM2A/7A inhibitors characterized by saturated indoline ring systems. The gene discussed is KDM2A; the disease is cancer.